DynaVox Under Intense Scrutiny

Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of purchasers of the securities of DynaVox Inc. (“DynaVox” or the “Company” ) concerning possible violations of federal securities laws. DynaVox designs, manufactures and distributes electronic and symbol-based augmentative communication equipment, software and services. The Company offers speech generating technology and special education software solutions for individuals with speech, language, physical or learning disabilities.

The investigation concerns allegations that certain statements made by the Company concerning its business and financial prospects were materially false and/or misleading. On September 30, 2010, the Company issued a press release stating that during its first quarter of fiscal 2011, DynaVox “experienced a softening of demand for both its speech generating devices and software products.” As a result, the Company announced, it is withdrawing its previously issued earnings guidance for fiscal year 2011. A subsequent article published by TheStreet.com noted “the weakness in DynaVox is striking given the company just went public in late April, selling upwards of 9 million shares at $15 each. The stock is now down 65% off a high of $19.20 on June 16.”

Important Information for DynaVox Shareholders

If you are a shareholder of DynaVox, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

DynaVox is based in Pittsburgh, PA.

Popularity: 1% [?]

Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/scln) have a class action lawsuit filed in the United States District Court for the Northern District of California on behalf of purchasers of SciClone Pharmaceuticals securities between May 11, 2009 and August 10, 2010.

SciClone develops therapeutics for the treatment of cancer and infectious diseases in China and internationally. The Complaint alleges the defendants were engaged in illegal and improper sales and marketing activities in China and abroad regarding its products.

The activities eventually caused SciClone to become the focus of a joint investigation by the SEC and the Department of Justice for possible violations of the Foreign Corrupt Practices Act.

Investors didn’t learn about the Company’s operations until it was reported the SEC and DOJ were investigating the Company for violations of the Act, and then Company shares declined almost 40% in one day, on abnormally large trading volume.

For more information about the case or to participate online, visit: www.rmclasslaw.com/cases/scln,
or contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218, or
by e-mail at rmaniskas@rmclasslaw.com.

Popularity: 1% [?]